| [1] |
Minisola S, Arnold A, Belaya Z, et al. Epidemiology, pathophysiology, and genetics of primary hyperparathyroidism[J]. J Bone Miner Res, 2022, 37(11): 2315-2329.
doi: 10.1002/jbmr.4665
pmid: 36245271
|
| [2] |
Tao X, Xu T, Lin X, et al. Genomic profiling reveals the variant landscape of sporadic parathyroid adenomas in Chinese population[J]. J Clin Endocrinol Metab, 2023, 108(7): 1768-1775.
doi: 10.1210/clinem/dgad002
pmid: 36611251
|
| [3] |
Bilezikian JP, Khan AA, Silverberg SJ, et al. Evaluation and management of primary hyperparathyroidism: summary statement and guidelines from the fifth international workshop[J]. J Bone Miner Res, 2022, 37(11): 2293-2314.
doi: 10.1002/jbmr.4677
pmid: 36245251
|
| [4] |
Zhu CY, Sturgeon C, Yeh MW. Diagnosis and management of primary hyperparathyroidism[J]. JAMA, 2020, 323(12): 1186-1187.
doi: 10.1001/jama.2020.0538
pmid: 32031566
|
| [5] |
中国研究型医院学会甲状旁腺及骨代谢疾病专业委员会, 中国研究型医院学会罕见病分会. 甲状旁腺癌诊治的专家共识[J]. 中华内分泌代谢杂志, 2019, 35(5): 361-368.
|
| [6] |
陈斯, 张晶晶, 洪天配. 甲状旁腺功能障碍与生殖功能[J]. 中华内分泌代谢杂志, 2021, 37(7): 673-676.
|
| [7] |
姚晓爱, 宋秀霞, 修磊, 等. 以抑郁症起病的原发性甲状旁腺功能亢进症一例报道并文献回顾[J]. 中华内分泌代谢杂志, 2021, 37(11): 1009-1012.
|
| [8] |
Wang SM, He Y, Zhu MT, et al. The associations of serum osteocalcin and cortisol levels with the psychological performance in primary hyperparathyroidism patients[J]. Front Endocrinol (Lausanne), 2021, 12: 692722.
doi: 10.3389/fendo.2021.692722
URL
|
| [9] |
He Y, Liu RX, Zhu MT, et al. The browning of white adipose tissue and body weight loss in primary hyperparathyroidism[J]. EBioMedicine, 2019, 40: 56-66.
doi: S2352-3964(18)30561-9
pmid: 30528454
|
| [10] |
Yuan TJ, Yang YY, Zhu MT, et al. Association of famine exposure on the changing clinical phenotypes of primary hyperparathyroidism in 20 years[J]. Front Endocrinol (Lausanne), 2022, 13: 907019.
doi: 10.3389/fendo.2022.907019
URL
|
| [11] |
Kim SJ, Shoback DM. Sporadic Primary Hyperparathyroidism[J]. Endocrinol Metab Clin North Am, 2021, 50(4): 609-628.
doi: 10.1016/j.ecl.2021.07.006
URL
|
| [12] |
Cusano NE, Cetani F. Normocalcemic primary hyperparathyroidism[J]. Arch Endocrinol Metab, 2022, 66(5): 666-677.
doi: 10.20945/2359-3997000000556
pmid: 36382756
|
| [13] |
Lowe H, McMahon DJ, Rubin MR, et al. Normocalcemic primary hyperparathyroidism: further characterization of a new clinical phenotype[J]. J Clin Endocrinol Metab, 2007, 92(8): 3001-3005.
doi: 10.1210/jc.2006-2802
URL
|
| [14] |
Šiprová H, Fryšák Z, Souček M. Primary hyperparathyroidism, with a focus on management of the normocalcemic form:to treat or not to treat?[J]. Endocr Pract, 2016, 22(3): 294-301.
doi: 10.4158/EP15704.OR
pmid: 26523628
|
| [15] |
Cusano NE, Maalouf NM, Wang PY, et al. Normocalcemic hyperparathyroidism and hypoparathyroidism in two community-based nonreferral populations[J]. J Clin Endocrinol Metab, 2013, 98(7): 2734-2741.
doi: 10.1210/jc.2013-1300
pmid: 23690312
|
| [16] |
Zhao L, Liu JM, He XY, et al. The changing clinical patterns of primary hyperparathyroidism in Chinese patients: data from 2000 to 2010 in a single clinical center[J]. J Clin Endocrinol Metab, 2013, 98(2): 721-728.
doi: 10.1210/jc.2012-2914
pmid: 23365127
|
| [17] |
王鸥, 邢小平, 孟迅吾, 等. 原发性甲状旁腺功能亢进症患者骨密度及胫骨超声速率的改变[J]. 诊断学理论与实践, 2006, 5(6): 499-502.
|
| [18] |
宋桉, 王鸥, 邢小平. GCM2突变相关原发性甲状旁腺功能亢进症的发病机制及临床特点[J]. 中华内分泌代谢杂志, 2022, 38(5): 437-439.
|
| [19] |
Lin X, Fan Y, Zhang Z, et al. Clinical Characteristics of primary hyperparathyroidism: 15-year experience of 457 patients in a single center in China[J]. Front Endocrinol (Lausanne), 2021, 12: 602221.
doi: 10.3389/fendo.2021.602221
URL
|
| [20] |
Cetani F, Pardi E, Marcocci C. Parathyroid carcinoma[J]. Front Horm Res, 2019, 51: 63-76.
doi: 10.1159/000491039
pmid: 30641523
|
| [21] |
胡亚, 廖泉. 甲状旁腺癌分子机制研究现状及临床应用前景[J]. 中华内分泌代谢杂志, 2020, 36(6): 537-540.
|
| [22] |
张冬雪, 魏伯俊, 姚晓爱, 等. 甲状旁腺肿瘤诊断中两种lncRNA评分模型的构建[J]. 中华内分泌代谢杂志, 2021, 37(12): 1061-1067.
|
| [23] |
Chen L, Shan C, Xu S, et al. Single-cell transcriptomic atlas of parathyroid adenoma and parathyroid carcinoma[J]. J Bone Miner Res, 2023, 38(7): 994-1005.
doi: 10.1002/jbmr.v38.7
URL
|
| [24] |
Schini M, Jacques R, Oakes E, et al. Normocalcaemic hyperparathyroidism and primary hyperparathyroidism: least significant change for adjusted serum calcium[J]. Eur J Endocrinol, 2021, 184(1): K7-K10.
doi: 10.1530/EJE-20-0634
pmid: 33112283
|
| [25] |
Yang YY, Zhang D, Ma LY, et al. Association of famine exposure and the serum calcium level in healthy Chinese adults[J]. Front Endocrinol (Lausanne), 2022, 13: 937380.
doi: 10.3389/fendo.2022.937380
URL
|
| [26] |
Zhu M, He Y, Liu T, et al. Factors that affect the sensitivity of imaging modalities in primary hyperparathyroidism[J]. Int J Endocrinol, 2021, 2021: 3108395.
|
| [27] |
Zhang M, Sun L, Rui W, et al. Semi-quantitative analysis of 99mTc-sestamibi retention level for preoperative differential diagnosis of parathyroid carcinoma[J]. Quant Imaging Med Surg, 2019, 9(8): 1394-1401.
doi: 10.21037/qims
URL
|
| [28] |
何泱, 孙立昊, 刘建民. 原发性甲状旁腺功能亢进症患者即使影像学定位不能确定也应手术探查治疗[J]. 中华内分泌代谢杂志, 2017, 33 (11): 920-922.
|
| [29] |
张浩, 贺亮. 定性明确而定位不明确的原发性甲状旁腺功能亢进症不应盲目手术[J]. 中华内分泌代谢杂志, 2017, 33(11): 923-924.
|
| [30] |
El-Hajj Fuleihan G, Clines GA, Hu MI, et al. Treatment of hypercalcemia of malignancy in adults: an endocrine society clinical practice guideline[J]. J Clin Endocrinol Metab, 2023, 108(3): 507-528.
doi: 10.1210/clinem/dgac621
URL
|
| [31] |
姜悦, 王鸥. 地舒单抗在高钙血症治疗中的应用[J]. 中华骨质疏松和骨矿盐疾病杂志, 2022, 15(3): 279-288.
|
)
